SMT Mobile Menu


Adalimumab Slows Progression of Erosive Hand OA

Adalimumab Slows Progression of Erosive Hand OA

FEATURED SEARCH TERM:   psoriatic arthritis

The tumor necrosis factor alpha blocker adalimumab can slow down progression of structural damage in erosive interphalangeal finger joint osteoarthritis, according to this double-blind, randomized placebo-controlled trial. Overall, adalimumab had no therapeutic effect on these hand osteoarthritis patients. The key predictor of erosive evolution appears to be soft tissue swelling.

Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification
Annals of the Rheumatic Diseases | Jun 1, 2012 (FREE FULL TEXT)

A recent randomized, placebo-controlled trial found that methotrexate had no disease-modifying effect in psoriatic arthritis. However, the trial design had issues, says the author of the report below, and other studies show methotrexate –  the most widely used medication for psoriatic arthritis – may have at least a moderate disease-modifying effect.

RESULT: Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?
Nature Reviews Rheumatology | May 2, 2012 (FREE FULL TEXT)


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.